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screening programme is highly cost-effective for further reducing
the burden of cervical cancer, pre-cancerous lesions and genital
warts in Belgium.
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OBJECTIVES: to assess the cost-effectiveness of alternative
quadrivalent human papillomavirus (HPV) vaccination strategies
in Norway. METHODS: A non-linear, deterministic, age-
structured, mathematical model of the transmission dynamics of
HPV infection (HPV types 6,11,16,18) and disease development
in the population was developed and integrated with an eco-
nomic model. Inputs for the model were obtained from public
data sources, published literature, and clinical trials. We assumed
a vaccine coverage rate of 90%. We varied duration of protection
from 10 years to lifetime. Current cervical cancer screening prac-
tices were assumed to remain unchanged with vaccination.
RESULTS: Vaccinating girls before the age of 12 augmented by a
female, 12–24-year olds temporary 5-year catch-up program was
the most effective strategy examined, reducing the incidence of
HPV 6/11/16/18-related genital warts, cervical intraepithelial
neoplasia (CIN1,2,3), and cervical cancer by 96%, 94%, and
94%, respectively 100 years following vaccine introduction.
Early reductions in disease and associated costs were primarily
attributable to prevention of infection with HPV types 6/11. For
example, 90% of the costs of HPV disease avoided and 92% of
the cases avoided during the ﬁrst 5 years was attributable to
preventing HPV 6/11 infection. However after 35 years, the
majority of HPV disease cost avoided was primarily attributable
to preventing HPV 16/18 infections. The cost-effectiveness ratio
for this strategy when compared with a strategy of vaccinating
females before the age of 12 was NOK61165 per quality adjusted
life year (QALY) gained. The following parameters were most
inﬂuential on the RESULTS: degree and duration of vaccine-
derived protection, vaccine coverage and costs, and preference
weights. CONCLUSION: A quadrivalent HPV (6,11,16,18)
vaccine national program can reduce the incidence of cervical
cancer, CIN (1,2,3), and genital warts and provide survival ben-
eﬁts and quality of life improvements at a cost-effectiveness ratio
within the range accepted as cost-effective for a reasonably wide
range of model input values.
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OBJECTIVES: Streptococcus pneumoniae is a frequent cause of
bacterial meningitis, septicaemia, pneumonia and acute otitis
media. These diseases lead to substantial mortality, morbidity
and costs. There is 7-valent pneumococcal conjugate vaccine
(PCV-7) developed, that has proved to be highly effective
against invasive disease, but has also provided signiﬁcant pro-
tection against pneumonia and acute otitis media. The objective
of this study was to evaluate the projected health beneﬁts,
costs and cost- effectiveness of vaccination with the 7-valent
conjugated pneumococcal vaccine compared with no vaccina-
tion, in all infants in Sweden. METHODS: An economic model
(Markov model) was used in order to perform a cost-utility and
a cost- effectiveness analysis, comparing a universal pneumococ-
cal vaccination program with a no-vaccination program. The
main outcomes were measured by reduction in the disease
burden, costs and net costs of vaccination (per individual and a
whole birth cohort), incremental cost per Quality adjusted life
years (QALY) and life year (LY) gained. RESULTS: The results
of the current health economic analysis indicate that a universal
pneumococcal vaccination program in Sweden could prevent a
considerable number of pneumococcal infections- mainly acute
otitis media infections- and reduce the related morbidity and
mortality. The incremental cost per QALY and LY gained was
estimated to range between SEK250,000 and SEK500,000. In
case herd immunity was included, the ICER was estimated to
range between 100,000 and 150,000 per QALY and LY gained.
CONCLUSION: The incremental cost per QALY gained advo-
cates that the health beneﬁts of vaccination in Sweden can be
achieved within generally accepted levels of cost per QALY. The
sensitivity analyses indicate that this conclusion is robust to
reasonable changes in the assumptions upon which the analysis
was based.
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OBJECTIVES: to assess the cost-effectiveness of alternative
quadrivalent human papillomavirus (HPV) vaccination strate-
gies in Hungary. METHODS: A non-linear, deterministic, age-
structured, mathematical model of the transmission dynamics
of HPV infection (6, 11, 16, 18) and disease development in the
population was developed and integrated with an economic
model. Inputs for the model were obtained from public data
sources, published literature, and clinical trials. We assumed a
vaccine uptake of 85% for routine vaccination and 10% for
catch-up vaccination. We varied duration of protection from 10
years to lifetime. Current cervical cancer screening practices
were assumed to remain unchanged with vaccination.
RESULTS: Vaccinating females before the age of 12 augmented
by a female, 12–24-year olds temporary 5-year catch-up
program was the most effective strategy examined, reducing the
incidence of HPV 6/11/16/18-related genital warts, cervical
intraepithelial neoplasia (CIN), and cervical cancer by 91%,
91%, and 94%, respectively one hundred years following
vaccine introduction. The cost-effectiveness ratio for this strat-
egy when compared with a strategy of vaccinating females
before the age of 12 was HUF2,501,750 per quality adjusted
life year (QALY) gained. The following parameters were most
inﬂuential on the RESULTS: degree and duration of vaccine-
derived protection, vaccine coverage and costs, and preference
weights. CONCLUSION: A quadrivalent HPV vaccination
program can reduce the incidence of cervical cancer, CIN, and
genital warts and provide survival beneﬁts and quality of life
improvements at a cost-effectiveness ratio within the range
accepted as cost-effective for a reasonably wide range of model
input values.
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